Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 BRL | +0.59% | +16.33% | -49.71% |
04-16 | UnitedHealth warns of $1.15-$1.35/share hit this year from hack | RE |
03-22 | Transcript : Qualicorp Consultoria e Corretora de Seguros S.A., Q4 2023 Earnings Call, Mar 22, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Its low valuation, with P/E ratio at 3.71 and 3.25 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Multiline Insurance & Brokers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-49.71% | 93.16M | B+ | ||
+9.73% | 110B | B- | ||
+8.61% | 99.67B | C+ | ||
+4.48% | 97.53B | B | ||
+0.07% | 69.25B | C+ | ||
+18.56% | 28.19B | A- | ||
+10.29% | 19.64B | A- | ||
-4.64% | 12.38B | B- | ||
+8.95% | 10.98B | A- | ||
+8.55% | 10.43B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QUAL3 Stock
- Ratings Qualicorp Consultoria e Corretora de Seguros S.A.